James Aloysius Brady Sells 10,834 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director James Aloysius Brady sold 10,834 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $5.54, for a total value of $60,020.36. Following the transaction, the director owned 89,166 shares in the company, valued at $493,979.64. This trade represents a 10.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Xeris Biopharma Stock Up 0.8%

Shares of XERS traded up $0.05 on Thursday, reaching $6.09. The stock had a trading volume of 365,669 shares, compared to its average volume of 2,009,358. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -608.29 and a beta of 0.61. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. The company has a 50-day simple moving average of $6.39 and a 200-day simple moving average of $7.31. Xeris Biopharma Holdings, Inc. has a 12-month low of $3.81 and a 12-month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The company had revenue of $85.81 million for the quarter, compared to analysts’ expectations of $86.00 million. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%. Sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on XERS. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a research report on Monday, March 2nd. Barclays assumed coverage on Xeris Biopharma in a research report on Monday, December 8th. They issued an “overweight” rating and a $9.00 price objective on the stock. Finally, Weiss Ratings raised Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Institutional Trading of Xeris Biopharma

A number of large investors have recently made changes to their positions in the stock. Royal Bank of Canada lifted its position in Xeris Biopharma by 1,411.2% during the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after purchasing an additional 198,984 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after buying an additional 3,594 shares during the last quarter. Millennium Management LLC raised its stake in Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after buying an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after buying an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP purchased a new position in shares of Xeris Biopharma in the 1st quarter worth $170,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.